MONDAY, March 18, 2013
Topics that will be focused on are:
Our therapeutic strategy ‘MPAC’ technology, what are these compounds like PBT2? Brief historical background as to where our HD program came from.  A bit of science (although without AV this will be brief indeed) Why we are hopeful that the mechanism of action may provide patient benefit.  In particular our previous work with PBT2 in AD. Outline of Reach2HD, status.